adaptimmune.com · 962
Adaptimmune is a clinical-stage biopharmaceutical company that is dedicated to developing novel cancer immunotherapy products for cancer patients. Our mission is personal as we strive to redefine the treatment of cancer. We are focused on solid tumor cancers and are using a personalized approach that has the potential to significantly enhance the patient experience. We envision a future where a single infusion could transform cancer care. The company's website provides detailed information about our company, pipeline, technology, patient resources, clinical trials, investor relations, and more.
adaptimmune.com · years statistic
2008
| 1 | 0 |
| 2 | 0 |
| 3 | 0 |
| 4 | 0 |
| 5 | 0 |
| 6 | 0 |
| 7 | 0 |
| 8 | 3 |
| 9 | 9 |
| 10 | 1 |
| 11 | 0 |
| 12 | 0 |
2009
| 1 | 1 |
| 2 | 0 |
| 3 | 1 |
| 4 | 0 |
| 5 | 0 |
| 6 | 0 |
| 7 | 0 |
| 8 | 0 |
| 9 | 0 |
| 10 | 0 |
| 11 | 0 |
| 12 | 0 |
2010
| 1 | 0 |
| 2 | 0 |
| 3 | 0 |
| 4 | 0 |
| 5 | 0 |
| 6 | 0 |
| 7 | 1 |
| 8 | 0 |
| 9 | 0 |
| 10 | 0 |
| 11 | 0 |
| 12 | 0 |
2011
| 1 | 1 |
| 2 | 5 |
| 3 | 0 |
| 4 | 0 |
| 5 | 0 |
| 6 | 0 |
| 7 | 0 |
| 8 | 0 |
| 9 | 2 |
| 10 | 0 |
| 11 | 0 |
| 12 | 0 |
2012
| 1 | 1 |
| 2 | 0 |
| 3 | 0 |
| 4 | 0 |
| 5 | 0 |
| 6 | 0 |
| 7 | 0 |
| 8 | 1 |
| 9 | 0 |
| 10 | 2 |
| 11 | 0 |
| 12 | 0 |
2013
| 1 | 0 |
| 2 | 0 |
| 3 | 3 |
| 4 | 0 |
| 5 | 1 |
| 6 | 0 |
| 7 | 1 |
| 8 | 1 |
| 9 | 4 |
| 10 | 0 |
| 11 | 2 |
| 12 | 1 |
2014
| 1 | 1 |
| 2 | 1 |
| 3 | 2 |
| 4 | 2 |
| 5 | 2 |
| 6 | 2 |
| 7 | 1 |
| 8 | 0 |
| 9 | 1 |
| 10 | 1 |
| 11 | 0 |
| 12 | 4 |
2015
| 1 | 0 |
| 2 | 2 |
| 3 | 1 |
| 4 | 3 |
| 5 | 1 |
| 6 | 1 |
| 7 | 2 |
| 8 | 2 |
| 9 | 3 |
| 10 | 2 |
| 11 | 0 |
| 12 | 1 |
2016
| 1 | 4 |
| 2 | 3 |
| 3 | 4 |
| 4 | 3 |
| 5 | 1 |
| 6 | 2 |
| 7 | 1 |
| 8 | 1 |
| 9 | 2 |
| 10 | 4 |
| 11 | 2 |
| 12 | 0 |
2017
| 1 | 2 |
| 2 | 0 |
| 3 | 0 |
| 4 | 0 |
| 5 | 1 |
| 6 | 5 |
| 7 | 7 |
| 8 | 2 |
| 9 | 6 |
| 10 | 3 |
| 11 | 4 |
| 12 | 2 |
2018
| 1 | 2 |
| 2 | 6 |
| 3 | 16 |
| 4 | 9 |
| 5 | 1 |
| 6 | 15 |
| 7 | 10 |
| 8 | 59 |
| 9 | 2 |
| 10 | 5 |
| 11 | 7 |
| 12 | 4 |
2019
| 1 | 1 |
| 2 | 1 |
| 3 | 1 |
| 4 | 2 |
| 5 | 2 |
| 6 | 1 |
| 7 | 3 |
| 8 | 4 |
| 9 | 1 |
| 10 | 0 |
| 11 | 3 |
| 12 | 3 |
2020
| 1 | 5 |
| 2 | 0 |
| 3 | 0 |
| 4 | 34 |
| 5 | 25 |
| 6 | 16 |
| 7 | 24 |
| 8 | 26 |
| 9 | 26 |
| 10 | 27 |
| 11 | 25 |
| 12 | 25 |
2021
| 1 | 20 |
| 2 | 22 |
| 3 | 15 |
| 4 | 13 |
| 5 | 14 |
| 6 | 11 |
| 7 | 3 |
| 8 | 3 |
| 9 | 2 |
| 10 | 14 |
| 11 | 45 |
| 12 | 43 |
2022
| 1 | 10 |
| 2 | 1 |
| 3 | 25 |
| 4 | 17 |
| 5 | 12 |
| 6 | 10 |
| 7 | 11 |
| 8 | 11 |
| 9 | 9 |
| 10 | 9 |
| 11 | 4 |
| 12 | 6 |
2023
| 1 | 5 |
| 2 | 11 |
| 3 | 10 |
| 4 | 8 |
| 5 | 5 |
| 6 | 12 |
| 7 | 4 |
| 8 | 6 |
| 9 | 3 |
| 10 | 25 |
| 11 | 2 |
| 12 | 6 |
2024
| 1 | 3 |
| 2 | 1 |
| 3 | 2 |
| 4 | 3 |
| 5 | 0 |
| 6 | 0 |
| 7 | 0 |
| 8 | 0 |
| 9 | 0 |
| 10 | 0 |
| 11 | 0 |
| 12 | 0 |
